Warby Parker (WRBY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.15
- Estimate
- $0.11
- Surprise
- +30.0%
- Revenue (period 2026-06-30)
- $235.5M
- Score at report (before → after)
- 4.5 → 4.5/10
Revenue source: xbrl.
How the report landed
Warby Parker (WRBY) beat the $0.11 estimate with adjusted EPS of $0.15 — a large 30.0% upside surprise. TrendMatrix's engine moved from Sell (4.5/10) to Hold at 4.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WRBY Sell at 5.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +30.0% surprise compares with a +3.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-1.3% upside)
- Risk below floor (2.2 < 2.5)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.33
- Stop
- $25.42
The stock trades at 354.8× trailing but 34.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: trading volume is running 2.2× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
WRBY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $2.63B
- P/E (fwd)
- 34.6
- P/E (ttm)
- 354.8
- 52-week range
- $14.96–$31.00
- Off 52-week high
- 11.8%
- RSI (14)
- 65
- Volume vs avg
- 2.18×
- Score today
- 5.1/10